Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 16,551 as of Wednesday, April 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,684 issues advancing vs. 1,250 declining with 198 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the industry include Dr. Reddy Laboratories ( RDY), up 2.7%, AbbVie ( ABBV), up 1.5%, Pfizer ( PFE), up 0.8%, Shire ( SHPG), up 0.7% and Novo Nordisk A/S ( NVO), up 0.6%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Mylan ( MYL) is one of the companies pushing the Drugs industry higher today. As of noon trading, Mylan is up $1.19 (2.4%) to $50.50 on average volume. Thus far, 2.8 million shares of Mylan exchanged hands as compared to its average daily volume of 4.7 million shares. The stock has ranged in price between $49.61-$50.98 after having opened the day at $49.68 as compared to the previous trading day's close of $49.31. Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $18.2 billion and is part of the health care sector. Shares are up 12.5% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.